Abstract: The invention relates to a process for producing mouldings by injection moulding the steps in the process being a) melting and mixing of a (meth)acrylate copolymer composed of from 85 to 98% by weight of C1-C4-alkyl (meth)acrylates capable of free-radical polymerization and from 15 to 2% by weight of (meth)acrylate monomers having a quaternary ammonium group in the alkyl radical, with from 10 to 25% by weight of a plasticizer, and also from 10 to 50% by weight of a dryers [sic] and/or from 0.1 to 3% by weight of a release agent, and, where appropriate, with other conventional pharmaceutical additives or auxiliaries and/or with an active pharmaceutical ingredient, b) devolatilizing the mixture at temperatures of at least 120° C., thus reducing the content of the low-boiling constituents with a vapour pressure of at least 1.9 bar at 120° C. to not more than 0.5% by weight, and c) injecting the devolatilized mixture at a temperature of from 80 to 160° C.

Abstract: The present invention provides an anti-itch sheet suitable for curing and relieving itching caused by an insect bite or sunburn based on a novel finding, the anti-itch sheet comprising a sealing layer, and a fixing layer on a skin-contacting side of the sealing layer for facilitating the application of the sealing layer to the skin.

Abstract: An ophthalmically acceptable vehicle includes an aqueous suspension having a first viscosity. The suspension includes about 0.1% to about 6.5% by weight of a carboxyl-containing polymer prepared by polymerizing one or more carboxyl-containing monoethylenically unsaturated monomers and less than about 5% by weight of a cross-linking agent. The polymer has average particle size of not more than about 50 ?m in equivalent spherical diameter. The vehicle includes a second polymer that allows the carboxyl-containing polymer to remain suspended. Upon contact with tear fluid, the vehicle gels to a second viscosity which is greater than the first viscosity. A method of administering a medicament to the eye of a subject includes applying a composition that includes this ophthalmically acceptable vehicle and a medicament contained for treatment of a disease or disorder for which ophthalmic delivery is indicated. The medicament is released from the vehicle in a sustained release manner.

Abstract: A pharmaceutical composition comprises nanoparticles comprising ionizable, poorly water soluble cellulosic polymers.

Abstract: A powder•particle dosage form obtained by granulating an excipient and/or a disintegrating agent with a liquid in which a bitter taste masking base is dissolved and/or suspended, and a drug having solubility in water (20° C.) of not higher than 1 g/mL is dissolved or suspended, or a tablet obtained by compressing the powder•particle dosage form could mask bitter taste of a drug.

Abstract: Personal care dissolvable films comprising a water soluble film forming agent, cosmetically acceptable plasticizer, and a thickener are described, along with methods of using the same.

Abstract: The present invention provides an aqueous dispersion of a low-molecular-weight polytetrafluoroethylene (PTFE), which contains an easily removable surfactant, and has a good dispersion stability. Specifically, the present invention provides an aqueous dispersion of a low-molecular-weight PTFE comprising tetrafluoroethylene (TFE) units, or TFE units and modifying monomer units which are copolymerizable with the TFE units, wherein the aqueous dispersion contains from 70 to 9,000 ppm, based on the aqueous dispersion, of a fluorine-containing compound of the formula (1) below: X—(CF2)m—Y??(1) where X is H or F; m is an integer from 3 to 5; and Y is —SO3M, —SO4M, —SO3R, —SO4R, —COOM, —PO3M2 or —PO4M2, M being H, NH4 or an alkali metal, and R being an alkyl group having 1 to 12 carbons, and the low-molecular-weight PTFE has an average primary particle size of from 100 to 350 nm.

Abstract: A copolymer obtainable by polymerization of a) at least one compound of the formula (I) (monomer ?) where R1 and R2, independently of one another, are in each case H or CH3, R3 is C6-C10-aryl or C7-C12-aralkyl which can carry one or more identical or different C1-C9-alkyl and/or C1-C5-alkoxy substituents, and n is an integer from 0 to 100, b) at least one compound chosen from the group of N-vinylamides, N-vinyllactams, N-vinylimines and N-vinylamines with 2 to 15 carbon atoms (monomer ?), c) if appropriate one or more different difunctional crosslinker components and d) if appropriate one or more different regulators and e) if appropriate one or more further copolymerizable components (monomer ?) is useful for increasing the systemicity of a pesticide.

Abstract: Preferred embodiment stimuli-responsive low solubility copolymer hydrogel compositions of the invention include polymerized N-isopropylacrylamide and water insoluble monomer or oligomer repeating units. The repeating units are arranged within the polymer backbone of the copolymer hydrogel. In a preferred fabrication method, precursors of N-isopropylacrylamide and precursors of the water insoluble monomer of oligomer are solved in a liquid solvent to form a solution in a container. An initiator is added to the solution. Gas is bubbled through the solution, and the container is sealed. The solution is stirred while heating to a polymerization temperature and polymerization is permitted to complete to form the copolymer hydrogel composition.

Abstract: The present disclosure relates to a container for pharmaceutical use for the quantitative release of a single-dose for oral administration of the T3 and T4 thyroid hormones in solution, characterized by the fact of being formed with a plastic material having a Young's modulus between 10 and 80 MPa.

Abstract: It is intended to provide a composition which has well-balanced pressure-sensitive adhesiveness and cohesive force as well as favorable application properties to the skin, and a patch which has the above-described characteristics and hardly peels off. This object can be achieved by providing a composition comprising an acrylic copolymer containing from 3 to 25% by weight of hydroxyethyl (meth)acrylate as a constituent, a plasticizer and a pseudo-crosslinking compound, wherein the ratio of the content of the plasticizer to the content of the pseudo-crosslinking compound ranges from 30:1 to 250:1, and a patch.

Abstract: An oil-in-water type emulsion contains a very small quantity of surfactant, so that the emulsion is stable, well tolerated and non-irritating. The emulsion is used as the base for compositions intended to be applied to sensitive tissues of the body of a human or animal, in particular in ophthalmic, dermatological and dermocosmetic compositions.

Abstract: A dosage form is disclosed comprising a semipermeable walled container that houses a capsule, which capsule comprises a drug formulation, a piston, and an osmotic composition. The dosage form delivers the drug formulation through a passageway at a controlled rate over a sustained-release period of time up to 24 hours.

Abstract: An active agent composition includes particles containing a water-insoluble active agent or an active agent with a significant food effect; and a ternary amine polymer having both hydrophobic (meth)acrylate units and acid-soluble (meth)acrylate units, and an acidifying agent; wherein upon ingestion by a human subject, the acidifying agent facilitates the dissolution of the ternary amine polymer in the gastrointestinal tract.

Abstract: A composition for bioactive agent release in vivo. The composition includes the bioactive agent in combination with a mixture of a first polymer component such as poly(butyl methacrylate) and a second polymer component such as poly(ethylene-co-vinyl acetate).

Abstract: The present invention relates to a process of forming a sprayable pesticide or herbicide formulation having improved spray drift properties comprising the steps of, i) providing an aqueous concentrate containing pesticide or herbicide, ii) providing an aqueous concentrate containing pesticidal or herbicidal adjuvant or fertiliser, iii) forming the sprayable pesticide or herbicide formulation by combining water, the pesticide or herbicide and the pesticidal or herbicidal adjuvant or fertiliser, wherein the aqueous concentrate of pesticide or herbicide and the aqueous concentrates of the pesticidal or herbicidal adjuvant or fertiliser both contain one or more polymers capable of enhancing spray drift control. The sprayable formulation may be prepared in a spray tank into which is metered water, the concentrate containing herbicide or pesticide and the concentrate containing the pesticidal or herbicidal adjuvant or fertiliser.

Abstract: A novel method of preparing a controlled release composition is disclosed. Specifically, the present invention relates to a method of preparing controlled release compositions of ascorbic acid phosphate and absorbable polymers. Also disclosed is a novel controlled release composition of ascorbic acid phosphate made by the method of the present invention.

Abstract: The present invention provides compositions, methods, and kits for treatment of opiate addiction and pain. The invention provides a biocompatible nonerodible polymeric device which releases buprenorphine continuously with generally linear release kinetics for extended periods of time. Buprenorphine is released through pores that open to the surface of the polymeric matrix in which it is encapsulated. The device may be administered subcutaneously to an individual in need of continuous treatment with buprenorphine.

Abstract: Biocompatible phase invertible proteinaceous compositions and methods for making and using the same are provided. The subject phase invertible compositions are prepared by combining a proteinaceous substrate and a crosslinking agent, such as a stabilized aldehyde crosslinking agent. Also provided are kits for use in preparing the subject compositions. The subject compositions, kits and systems find use in a variety of different applications.

Abstract: Disclosed herein is a pharmaceutical composition, containing a thiazide compound and an angiotensin-II-receptor blocker, and a technology for formulating the same. More particularly, disclosed is a pharmaceutical combination formulation of thiazide compound and angiotensin-II-receptor blocker, which maximizes the pharmacological and clinical antihypertensive effects and complication preventive effects of the drugs and reduces the side effects of the drugs, compared to when single-component formulations of the drugs are administered simultaneously.

Abstract: The present invention can provide a composition for a medical material or a hygiene material, which can retain a considerable amount of a chemical substance such as a drug and the like or an organic liquid component, is associated with less limitation on molding, does not easily drop off when adhered to the skin, provides a better feeling during adhesion to the skin, produces decreased adhesive residue when detached from the skin, and shows good followability to the skin. The present invention provides a gel composition obtained by crosslinking a composition for gel preparation comprising a liquid rubber having a crosslinkable functional group in a molecule and 34.6-64.6 wt % of an organic liquid component relative to the total weight of the composition for gel preparation.

Abstract: Pharmaceutical formulations comprising a multi-phasic pharmaceutical composition, and an adsorbent carrier, where the pharmaceutical formulation is a solid dosage form. Methods for preparing such pharmaceutical compositions are described.

Abstract: Composition comprising an oil phase, an aqueous phase, at least one emulsifying system of water-in-oil (W/O) type, optionally at least one emulsifying system of 5 oil-in-water (O/W) type, in the form of an inverse latex comprising from 10% to 80% by mass and preferably from 20% to 70% by mass and most preferably from 30% to 60% by mass, of a linear partially or totally salified anionic polyelectrolyte, with wherein in that said oil phase comprises a silicone oil or a mixture of silicone oils; its use to thicken and or to emulsify cosmetic; dermopharmaceutical or pharmaceutical compositions.

Abstract: A composition of an oral medicine or an oral medicine which can prevent an unpleasant taste of the medicine is herein disclosed. It is granules, powders, syrups and the like which is prevented from an unpleasant taste, comprising a basic medicine having an unpleasant taste and an anionic polymer such as carrageenan.

Abstract: According to an aspect of the present invention, implantable or insertable medical devices are provided, which contain one or more polymeric regions, which in turn contain at least one block copolymer. The block copolymer includes (a) at least one high Tg (glass transition temperature) polymer block that contains at least one high Tg vinyl ether monomer and (b) at least one low Tg polymer block that contains at least one low Tg vinyl ether monomer.

Abstract: This invention provides biodegradable, sustained-release pharmaceutical compositions of a psychoactive drug formulated with biocompatible, biodegradable tyrosine-derived polyarylates.

Abstract: Certain diacylglycerol-polyethyleneglycol (DAG-PEG) lipids are especially useful for forming thermodynamically stable liposomes. Such liposomes are useful for a variety of purposes, including the delivery of therapeutic agents.

Abstract: Coated particles of metal (such as calcium) silicate that exhibit excellent odor neutralization and sebum absorption properties when present within certain cosmetic and/or personal care formulations and suspensions are provided. Uncoated calcium silicate exhibits a high pH level that may have a deleterious effect upon such cosmetic and/or personal care compositions, thereby rendering the overall composition ineffective for its intended purpose, particularly if the calcium silicate is present in its usual state at high loading levels. Alternatively, if certain materials present within personal care compositions exhibit a sufficiently low pH level, the effectiveness of such calcium silicates may be compromised as well.

Abstract: A method and device for treating a mammalian organism to obtain a desired local or systemic physiological or pharmacological effect is provided. The method includes administering a sustained release drug delivery system to a mammalian organism in need of such treatment at an area wherein release of an effective agent is desired and allowing the effective agent to pass through the device in a controlled manner. The device includes an inner core or reservoir including the effective agent, an impermeable tube which encloses portions of the reservoir, and a permeable member at an end of the tube.

Abstract: An object of the present invention is to provide a liposome which is excellent in intrapulmonary delivery controllability of drugs or genes and is suited for pulmonary administration. By modifying the surface of a liposome using a terminal hydrophobized polyvinyl alcohol and/or chitosan, retention of drugs or genes encapsulated in the liposome on the surface of lung tissue and transfer of drugs or genes into lung tissue can be properly modulated, and thus in vivo behavior can be controlled.

Abstract: Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue.

Abstract: With an object of providing an orally administered agent (in particular a film-shaped orally administered agent) with which the ease and safety of taking the agent are improved, to attain this object, in an orally administered agent 1b having one drug-containing layer 11 and two water-swellable gel-forming layers 12, the water-swellable gel-forming layers 12 are provided, either directly or via intermediate layers, on the both faces of the drug-containing layer 11.

Abstract: Compositions for treating hair are disclosed. Methods of making and using compositions for treating hair are also disclosed.

Abstract: This invention relates to an extended release formulation comprising a solid non-steroidal non-ionized hydrophilic drug, having a molecular weight below 500 Dalton and having a solubility of at least 0.1 wt % in ethylene vinyl acetate copolymer having a vinyl acetate content of 28%, which formulation is a vaginal device having a skin and which device comprises an inner compartment made of a thermoplastic polymer, which polymer is containing the drug. The polymer is preferably made of ethylene-vinyl acetate copolymer.

Abstract: The invention provides a process for making hollow microparticles. The process comprises providing a dispersion having a continuous aqueous phase and a discontinuous organic phase and polymerising a monomer in the dispersion to form hollow polymeric microparticles. The continuous aqueous phase of the dispersion comprises a stabiliser and the discontinuous organic phase of the dispersion comprises the monomer and an organic liquid. The monomer has two or more polymerisable groups per molecule. Prior to the step of polymerising the monomer, the discontinuous organic phase does not contain a polymer.

Abstract: Coatings with crystallized active agent(s) and related methods are disclosed. One method includes selecting a solvent and a polymer, selecting a concentration of an active agent of at least a certain amount of saturation, forming a coating composition having the selected concentration of the active agent, and applying the coating composition to the medical device. Also disclosed is an elution control coating which includes active agent that is at least about 80% crystallized within one week of being disposed on a medical device. One method enhances the formation of active agent crystals within a coating layer by adjusting the concentration of the active agent in the coating solution to reach some percentage of the active agent saturation point. Another method includes increasing the rate of active agent nucleation within the coating.

Abstract: The invention relates to a copolymer including betaininc units and hydrophobic and/or amphiphile units. The invention also relates to a method for preparing a copolymer including betaininc units and hydrophobic and/or amphiphile units, by controlled micellar polymerisation. The invention further relates to the uses of the copolymer. The copolymer is particularly used for increasing the viscosity of saline aqueous compositions.

Abstract: A contact lens care solution comprising: a cationic antimicrobial component having an average molecular weight (MNA), and a cationic oligomer or nitrogen/amine oligomer having a number average molecular weight (MNO) from 500 daltons to 15,000 daltons. The lens care solutions are used to clean and disinfect contact lenses, and in particular, soft, silicone hydrogel contact lenses.

Abstract: The present invention comprises the use of formulations comprising at least one pesticide and at least one co-polymer comprising (a) at least one comonomer (a) selected from the group consisting of olefins, vinylethers, vinyl pyrrolidone and styrene; and (b) at least one comonomer (b) selected from the group consisting of ethylenically unsaturated dicarboxylic mono and diesters, wherein the alcohol moiety of the mono- or diester has the structure of formula I wherein R1 is 1,2-propylene or 2,3 propylene R2 is ethylene; R3 is hydrogen, branched or linear C1-C40, preferably C1-C24 alkyl, phenyl, phenyl substituted with C1-C20 alkyl, benzyl, benzyl substituted with C1-C20 alkyl; n corresponds to a value from 0 to 140, preferably 0-50, more preferably 0-20. p corresponds to a value from 0 to 100 wherein the sum of n and p is at least 1, preferably 1-60, most preferably 5-40.

Abstract: Disclosed are sterile hydrogel compositions comprising polyvinyl alcohol (“PVA”), polyvinyl pyrrolidone (“PVP”), and a polysaccharide, wherein the combined amount of PVA and PVP present in the hydrogel compositions is from about 2% to about 12% weight by volume, based on the total volume of the composition, and wherein the hydrogel compositions has a gel fraction greater than or equal to 97%. Sterile hydrogel products including such sterile hydrogel compositions, and methods of making such sterile hydrogel compositions and sterile hydrogel products.

Abstract: The present invention relates to cosmetic or dermatological formulations comprising at least one active compound, at least one polymer which is molecularly imprinted in the presence of this active compound and at least one fatty phase.

Abstract: According to the invention glyceryl monostearate and a polymeric binder are employed as a spheronising aid in the manufacture of pharmaceutical spheroids containing no or substantially no microcrystalline cellulose. The spheroids can contain one or more therapeutically active agent which undergoes no or substantially no degradation when stored under accelerated temperature and humidity conditions. A coating may be applied to the spheroids; when present, the coating is preferably a controlled release coating.

Abstract: Materials and methods for the generation of polyelectrolyte multilayers that can erode to release cationic components. The multilayers comprise layers that contain one or more cations and one or more charge-dynamic anionic polymers. Charge-dynamic anionic polymers contain side chains having removable functional groups. Removal of the functional groups results in a change in the net change in the charge of the polymer which can disrupt interactions between cations and the anionic polymers and facilitate release of cations.

Abstract: The invention features biodegradable polymers for the delivery of biologically active agents. The polymers include at least one biologically active agent covalently attached via a polyamide linker susceptible to selective hydrolysis by peptidase enzymes. Hydrolysis of the polyamide linker releases the biologically active agent in vivo.

Abstract: Transdermal drug delivery patches and methods of their production are described. The patches can be made such that the accommodate highly plasticizing drugs such as selegiline and/or the use of protonated forms of various drugs.

Abstract: Fixation devices for tissue repair, for example sutures, surgical arrows, staples, darts, bolts, screws, buttons, anchors, nails, rivets, or barbed devices comprise at least one of angiogenic material; angiogenic precursor material which is capable of breaking down in vivo to form angiogenic material; or tissue-engineered material, which tissue-engineered material is capable of producing angiogenic material. In a preferred form, the material is incorporated into a polymer matrix having predetermined hydrophobicity to allow controlled release of angiogenic materials such as butyric or hydroxybutyric acid or salts thereof. Polymer matrix compositions comprising angiogenic materials and methods for tissue repair are also provided.

Abstract: The present invention is a thickener consisting of a microgel obtained by radical polymerization of water soluble ethylene-type unsaturated monomers dissolved in the dispersion phase in a composition having an organic solvent or an oil component as the dispersion medium and water as the dispersion phase, as well as a cosmetic containing said thickener.

Abstract: The invention relates to a solid oral dosage form comprising a pharmaceutically active ingredient in combination with an enhancer which enhances the bioavailability and/or the absorption of the active ingredient. Accordingly, a solid oral dosage form comprises a drug and an enhancer wherein the enhancer is a medium chain fatty acid ester, ether or salt or a derivative of a medium chain fatty acid, which is, preferably, solid at room temperature and which has a carbon chain length of from 6 to 20 carbon atoms. Preferably, the solid oral dosage form is controlled release dosage form such as a delayed release dosage form.

Abstract: A method of lowering the surface tension or the interface tension of water in cosmetic compositions comprising at least one cosmetic or dermatological adjuvant, the method comprising adding a polymer comprising water-soluble units and units with an LCST, wherein the LCST units an have in water a demixing temperature of from 5 to 40° C. for a concentration of 1% by mass is used, the polymer being present in a concentration such that the gel point of the aqueous phase is from 5 to 40° C., to ensure the stability of the dispersions at temperatures from 4° C. to 50° C.

Abstract: Biocompatible polymers are manufactured to include an ammo acid mimetic monomer and one or more hydrophobic acrylate monomers. The amino acid mimetic monomers are selected to mimic the side chain of the amino acids asparagine or glutamine. The amino acid mimetic monomer can be a methacryloyl or acryloyl derivative of 2-hydroxyacetamide, 3-hydroxypropionamide, alaninamide, lactamide, or glycinamide. These amide functional groups offer the advantage of moderate hydrophilicity with little chemical reactivity. The amino acid mimetic monomer can be copolymerized with one or more hydrophobic acrylate monomers to obtain desired coating properties.